Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

被引：0
|
作者：
Brian R. Ott
Lesley M. Blake
Ethel Kagan
Malca Resnick
机构：
[1] Rhode Island Hospital – APC 6,The Alzheimer’s Disease & Memory Disorders Center
[2] Northwestern University,Department of Psychiatry
[3] Harborside Financial Center,Forest Laboratories, Inc.
来源：
Journal of Neurology | 2007年 / 254卷
关键词：
Alzheimer’s disease; memantine; open label; randomized controlled trial; ADAS-cog;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：351 / 358
页数：7
相关论文
共 50 条
  • [41] A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease
    Patterson, CE
    Passmore, AP
    Crawford, VLS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (02) : 144 - 148
  • [42] Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease:: multicenter trial
    Pirttilä, T
    Wilcock, G
    Truyen, L
    Damaraju, CV
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (11) : 734 - 741
  • [43] Efficacy, safety, and response predictors of Astragalus in patients with mild to moderate Alzheimer's disease: A study protocol of an assessor-blind, statistician-blind open-label randomized controlled trial
    Cheng, Yingzhe
    Lin, Lin
    Huang, Peilin
    Zhang, Jiejun
    Pan, Xiaodong
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 41
  • [44] Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease
    Doody, R
    Wirth, Y
    Schmitt, F
    Möbius, HJ
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 18 (02) : 227 - 232
  • [45] Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study
    Michael Rainer
    A. Wuschitz
    C. Jagsch
    C. Erb
    J.-J. Chirikdjian
    H. A. M. Mucke
    Journal of Neural Transmission , 2011, 118
  • [46] Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study
    Rainer, Michael
    Wuschitz, A.
    Jagsch, C.
    Erb, C.
    Chirikdjian, J. -J.
    Mucke, H. A. M.
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (08) : 1255 - 1259
  • [47] Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
    Burns, A.
    Gauthier, S.
    Perdomo, C.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2007, 22 (08) : 806 - 812
  • [48] The safety and tolerability of donepezil in patients with Alzheimer's disease
    Jackson, S
    Ham, RJ
    Wilkinson, D
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 : 1 - 8
  • [49] Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks
    Guthrie, Heather
    Honig, Lawrence S.
    Lin, Helen
    Sink, Kaycee M.
    Blondeau, Kathleen
    Quartino, Angelica
    Dolton, Michael
    Carrasco-Triguero, Montserrat
    Lian, Qinshu
    Bittner, Tobias
    Clayton, David
    Smith, Jillian
    Ostrowitzki, Susanne
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 76 (03) : 967 - 979
  • [50] Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer's Disease Dementia
    Hsieh, Sun-Wung
    Chen, Jui-Cheng
    Chen, Nai-Ching
    Jhang, Kai-Ming
    Wang, Wenfu
    Yang, Yuan-Han
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021, 19 (03) : 447 - 457
12345